Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is an American medical device company that designs, manufactures, and markets transcatheter and surgical heart valve therapies, generating $6.07 billion in revenue in fiscal 2025. It is the dominant global player in transcatheter aortic valve replacement (TAVR), a procedure that has transformed the treatment of aortic stenosis from a high-risk open-heart surgery into a minimally invasive catheter-based intervention — performed on more than 1.2 million patients worldwide using the company's SAPIEN platform. Edwards also competes in the faster-growing transcatheter mitral and tricuspid repair and replacement market and in the mature surgical structural heart market, operating as a pure-play after divesting its Critical Care business in 2024.

This is a story about a franchise whose competitive moat — built from more than 15 years of randomized clinical evidence, 10 New England Journal of Medicine publications, and an installed base of over a million treated patients — continues to widen even as its core TAVR market matures from a hyper-growth category into a durable high-single-digit compounder. The company carries $3.5 billion in net cash on its balance sheet, invests nearly 18% of revenue in R&D, and is in the early innings of building a second franchise in transcatheter mitral and tricuspid therapies that crossed half a billion dollars in revenue in 2025. The file turns on a single question: whether the TMTT portfolio can grow into a second growth engine large enough to offset the natural deceleration of TAVR, and whether the emerging evidence for treating asymptomatic and moderate aortic stenosis patients expands the addressable market faster than competition, pricing pressure, and the weight of expectations erode the existing one.